BRAF inhibitor dabrafenib alone vs combination with MEK1/2 inhibitor trametinib for melanoma

Share :
Published: 29 Sep 2012
Views: 8311
Dr Georgina Long - Melanoma Institute Australia, Sydney, Australia

Dr Georgina Long from Westmead Hospital and the Melanoma Institute Australia reported at a press conference at ESMO 2012 in Vienna that combining the new drugs dabrafenib and trametinib provided a clinically meaningful improvement in progression-free survival, response rate and duration of response in 162 patients with melanoma that had BRAF V600 mutations.


ecancerNews coverage from ESMO 2012